Physician profile
William D Irvine
NPI 1760488498
$10,732.87
in general payments reported to CMS, 2019-2025
38 companies · $924 in 2025
The $924 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $296 · 2021: $920 · 2022: $720 · 2023: $6,282 · 2024: $1,088 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,361 · Food and Beverage: $2,933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,360.94 |
| Food and Beverage | $2,932.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $5,343.75 | 2023 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Abbvie INC. | $650.88 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $554.01 | 2019-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $451.10 | 2022-2025 | Syfovre |
| Notal Vision, INC. | $375.81 | 2021 | |
| Mallinckrodt Hospital Products INC. | $356.59 | 2020-2023 | Acthar |
| Bausch & Lomb Americas INC. | $331.89 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Genentech USA, INC. | $306.01 | 2022-2025 | Vabysmo |
| Allergan, INC. | $284.00 | 2019-2021 | |
| Alimera Sciences, INC. | $212.63 | 2019-2023 | Iluvien |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $203.62 | 2019-2021 | |
| Harrow Eye, LLC | $160.84 | 2024-2025 | Vevye |
| Ocular Therapeutix, INC. | $150.54 | 2020-2025 | Dextenza |
| Novartis Pharmaceuticals Corporation | $144.06 | 2019-2023 | |
| Horizon Therapeutics Plc | $123.55 | 2023 | Tepezza |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $96.36 | 2024-2025 | Purified Cortrophin Gel, Yutiq |
| Shire North American Group INC | $89.65 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $88.98 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $87.70 | 2019-2021 | |
| Dompe US, INC. | $86.38 | 2024-2025 | Oxervate |
| Oyster Point Pharma, INC. | $76.86 | 2022-2025 | Ryzumvi, Tyrvaya |
| Boston Scientific Corporation | $62.02 | 2023-2025 | Wavewriter Alpha Prime 16 |
| Thea Pharma INC. | $60.64 | 2024-2025 | Iyuzeh |
| Coherus Oncology, INC. | $57.01 | 2022-2023 | |
| Alcon Vision LLC | $49.23 | 2019-2023 | Clareon |
| Biotissue Holdings INC. | $40.16 | 2024-2025 | |
| Beaver-Visitec International, INC. | $39.31 | 2022 | |
| Dutch Ophthalmic, USA | $29.58 | 2023 | Eva, Combined Machine, Tissueblue |
| Kala Pharmaceuticals, INC. | $27.99 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $27.77 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $27.29 | 2024 | Xdemvy |
| Biogen, INC. | $26.82 | 2022 | |
| Amgen INC. | $23.15 | 2025 | Tepezza |
| Astellas Pharma US INC | $22.45 | 2024 | Izervay |
| Mallinckrodt Enterprises LLC | $19.66 | 2019 | |
| Rayner Intraocular Lenses Limited | $15.10 | 2025 | Omidria |
| Glaukos Corporation | $14.96 | 2025 | Idosetr |
| Eyevance Pharmaceuticals LLC | $14.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Irvine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.